<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4466">
  <stage>Registered</stage>
  <submitdate>13/12/2012</submitdate>
  <approvaldate>13/12/2012</approvaldate>
  <nctid>NCT01751906</nctid>
  <trial_identification>
    <studytitle>ABSORB III Randomized Controlled Trial (RCT)</studytitle>
    <scientifictitle>A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions.</scientifictitle>
    <utrn />
    <trialacronym>ABSORB-III</trialacronym>
    <secondaryid>10-392</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Artery Disease</healthcondition>
    <healthcondition>Coronary Artery Stenosis</healthcondition>
    <healthcondition>Coronary Disease</healthcondition>
    <healthcondition>Coronary Stenosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Absorb BVS
Treatment: devices - XIENCE

Experimental: Absorb BVS - Subjects receiving Absorb BVS

Active Comparator: XIENCE - Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition


Treatment: devices: Absorb BVS
Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length = 24 mm) with a reference vessel diameter of = 2.5 mm and = 3.75 mm.

Treatment: devices: XIENCE
Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length = 24 mm) with a reference vessel diameter of = 2.5 mm and = 3.75 mm.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Target Lesion Failure (TLF) at 1 year, non-inferiority (NI) against the control. - TLF is defined as composite of Cardiac Death, Myocardial Infarction (per protocol-defined MI definition), attributable to Target Vessel (TV-MI), or Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Sample size of 1900 subjects is required for the study (2:1 randomization); 1267 subjects for Absorb BVS arm and 633 subjects for XIENCE arm. Assuming a 5% dropout rate approximately 2,000 subjects will be required
The ABSORB III primary endpoint of TLF at 1-year follow up will be analyzed for the intention-to-treat (ITT) and the per-treatment evaluable (PTE) populations. The primary analysis will be based on the ITT population. The non-inferiority hypothesis testing will be performed using a non-inferiority test statistic by Farrington and Manning. Non-inferiority of Absorb BVS to XIENCE will be established if the p-value for the non-inferiority test is less than 0.025.</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Powered Imaging Cohort Secondary Endpoint: The in-stent/scaffold mean lumen diameter change, between pre- and post-nitrate infusion at 3 years by angiography - Pooled angiographic subjects (~600 subjects): 200 subjects from the Imaging Cohort of ABSORB III and 400 subjects from the ABSORB Japan RCT.</outcome>
      <timepoint>Post-procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Powered Imaging Cohort Secondary Endpoint: The in-stent/scaffold mean lumen diameter change, between pre- and post-nitrate infusion at 3 years by angiography - Pooled angiographic subjects (~600 subjects): 200 subjects from the Imaging Cohort of ABSORB III and 400 subjects from the ABSORB Japan RCT.</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Powered Imaging Cohort Secondary Endpoint: The in-stent/scaffold mean lumen area change, from post-procedure to 3 years by intravascular ultrasound (IVUS) - Mean lumen area measured after nitrate infusions, superiority test, ~300 pooled subjects.
Pooled IVUS subjects (~300 subjects): 150 subjects from the Imaging Cohort of ABSORB III RCT and 150 subjects from ABSORB Japan RCT.</outcome>
      <timepoint>Post-procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Powered Imaging Cohort Secondary Endpoint: The in-stent/scaffold mean lumen area change, from post-procedure to 3 years by IVUS - Mean lumen area measured after nitrate infusions, superiority test, ~300 pooled subjects.
Pooled IVUS subjects (~300 subjects): 150 subjects from the Imaging Cohort of ABSORB III RCT and 150 subjects from ABSORB Japan RCT.</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Powered Secondary Endpoint: Angina - This powered secondary endpoint is intended to assess angina at 1 year and test for superiority of Absorb BVS to XIENCE.
Angina is defined as the first adverse event resulting in the site diagnosis of angina.
The analysis will exclude angina following the index procedure through discharge, not to exceed a period of 7 days.
This analysis will include ~2000 subjects.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Powered Secondary Endpoint: Diabetic Indication - The powered secondary endpoint will be to support a diabetic indication for Absorb BVS.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Acute Success- Device success (Lesion level analysis) - Successful delivery and deployment of the study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 30% by quantitative coronary angiography (QCA) (by visual estimation if QCA unavailable). When bailout scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment is not one of the criteria for device success.</outcome>
      <timepoint>From the start of index procedure to end of index procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Acute Success- Procedural success (Subject level analysis) - Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days).</outcome>
      <timepoint>From the start of index procedure to end of index procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>During hospital stay</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>During hospital stay</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia driven-Target Lesion Revascularization (ID-TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>During hospital stay</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia driven-Target Lesion Revascularization (ID-TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia driven-Target Lesion Revascularization (ID-TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia driven-Target Lesion Revascularization (ID-TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia driven-Target Lesion Revascularization (ID-TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia driven-Target Lesion Revascularization (ID-TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia driven-Target Lesion Revascularization (ID-TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia driven-Target Lesion Revascularization (ID-TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non ID-TLR (NID-TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>During hospital stay</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non ID-TLR (NID-TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non ID-TLR (NID-TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non ID-TLR (NID-TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non ID-TLR (NID-TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non ID-TLR (NID-TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non ID-TLR (NID-TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non ID-TLR (NID-TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia driven-Target Vessel Revascularization (ID-TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</outcome>
      <timepoint>During hospital stay</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia driven-Target Vessel Revascularization (ID-TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia driven-Target Vessel Revascularization (ID-TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia driven-Target Vessel Revascularization (ID-TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia driven-Target Vessel Revascularization (ID-TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia driven-Target Vessel Revascularization (ID-TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia driven-Target Vessel Revascularization (ID-TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia driven-Target Vessel Revascularization (ID-TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non ID-TVR (NID-TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</outcome>
      <timepoint>During hospital stay</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non ID-TVR (NID-TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non ID-TVR (NID-TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non ID-TVR (NID-TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non ID-TVR (NID-TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non ID-TVR (NID-TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non ID-TVR (NID-TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non ID-TVR (NID-TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>During hospital stay</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.</outcome>
      <timepoint>During hospital stay</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>During hospital stay</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>During hospital stay</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE)</outcome>
      <timepoint>During hospital stay</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE)</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE)</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE)</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE)</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE)</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE)</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE)</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (Target Vessel Failure, TVF)</outcome>
      <timepoint>During hospital stay</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF)</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF)</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF)</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF)</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF)</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF)</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF)</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>During hospital stay</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Timing (acute, sub-acute, late and very late)</outcome>
      <timepoint>During hospital stay</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Timing (acute, sub-acute, late and very late)</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Timing (acute, sub-acute, late and very late)</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Timing (acute, sub-acute, late and very late)</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Timing (acute, sub-acute, late and very late)</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Timing (acute, sub-acute, late and very late)</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Timing (acute, sub-acute, late and very late)</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Timing (acute, sub-acute, late and very late)</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Evidence (Definite, Probable and Possible)</outcome>
      <timepoint>During hospital stay</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Evidence (Definite, Probable and Possible)</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Evidence (Definite, Probable and Possible)</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Evidence (Definite, Probable and Possible)</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Evidence (Definite, Probable and Possible)</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Evidence (Definite, Probable and Possible)</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Evidence (Definite, Probable and Possible)</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Evidence (Definite, Probable and Possible)</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on TLF and components</outcome>
      <timepoint>1-3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on TLF and components</outcome>
      <timepoint>1-4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on TLF and components</outcome>
      <timepoint>1-5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on scaffold thrombosis/stent thrombosis (per ARC definition, definite and probable)</outcome>
      <timepoint>1-3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on scaffold thrombosis/stent thrombosis (per ARC definition, definite and probable)</outcome>
      <timepoint>1-4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on scaffold thrombosis/stent thrombosis (per ARC definition, definite and probable)</outcome>
      <timepoint>1-5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Optical Coherence Tomography (OCT) endpoint - All OCT endpoints will be collected for within the device and within the treated segment:
Descriptive analysis of strut, lesion and vessel morphology Mean neointimal area (NIA) - Apposed to the vessel wall with neointimal coverage Apposed to vessel wall without neointimal coverage Incomplete apposition to vessel wall with neointimal coverage Incomplete apposition to vessel wall without neointimal coverage Lumen area/volume stenosis % Mean/minimal device area Mean/minimal luminal area/volume Mean strut area/volume Persisting incomplete apposition, late incomplete apposition at 3 years (if analyzable) OCT analysis for subjects with jailed side branch Descriptive analyses from 3-dimensional OCT reconstructions</outcome>
      <timepoint>Post-procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Optical Coherence Tomography (OCT) endpoint - All OCT endpoints will be collected for within the device and within the treated segment:
Descriptive analysis of strut, lesion and vessel morphology Mean neointimal area (NIA) - Apposed to the vessel wall with neointimal coverage Apposed to vessel wall without neointimal coverage Incomplete apposition to vessel wall with neointimal coverage Incomplete apposition to vessel wall without neointimal coverage Lumen area/volume stenosis % Mean/minimal device area Mean/minimal luminal area/volume Mean strut area/volume Persisting incomplete apposition, late incomplete apposition at 3 years (if analyzable) OCT analysis for subjects with jailed side branch Descriptive analyses from 3-dimensional OCT reconstructions</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>General 

          1. 18 years of age.

          2. Subject or a legally authorized representative must provide written Informed Consent
             prior to any study related procedure, per site requirements.

          3. Subject must have evidence of myocardial ischemia. In the absence of noninvasive
             ischemia, fractional flow reserve (FFR) must be done and indicative of ischemia.

          4. Acceptable candidate for coronary artery bypass graft (CABG) surgery.

          5. Female subject of childbearing potential who does not plan pregnancy for up to 1 year
             following the index procedure. For a female subject of childbearing potential a
             pregnancy test must be performed with negative results known within 7 days prior to
             the index procedure per site standard.

          6. Female subject is not breast-feeding at the time of the screening visit and will not
             be breast-feeding for up to 1 year following the index procedure.

          7. Subject agrees to not participate in any other investigational or invasive clinical
             study for a period of 1 year following the index procedure.

        General</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Any surgery requiring general anesthesia or discontinuation of aspirin and/or an
             adenosine diphosphate (ADP) antagonist is planned within 12 months after the
             procedure.

          2. Hypersensitivity or contraindication to device material and its degradants
             (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and cobalt,
             chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be
             adequately pre-medicated. Subject has a known contrast sensitivity that cannot be
             adequately pre-medicated.

          3. Allergic reaction, hypersensitivity or contraindication to aspirin; or to clopidogrel
             and prasugrel and ticagrelor; or to heparin and bivalirudin, and therefore cannot be
             adequately treated with study medications.

          4. Acute myocardial infarction (AMI: STEMI or NSTEMI) within 72 hours of the index
             procedure and both creatine kinase (CK) and CK-MB have not returned to within normal
             limits at the time of index procedure; or subject with stable angina or silent
             ischemia has CK-MB that is greater than normal limits at the time of the index
             procedure.

          5. Subject is currently experiencing clinical symptoms consistent with new onset AMI
             (STEMI or NSTEMI), such as nitrate-unresponsive prolonged chest pain with ischemic ECG
             changes.

          6. Cardiac arrhythmia as identified at the time of screening for which at least one of
             the following criteria is met:

             (NOTE: Investigator should use discretion when enrolling subjects with high CHADS
             scores)

               1. Subject requires coumadin or any other agent for chronic oral anticoagulation

               2. Subject is likely to become hemodynamically unstable due to their arrhythmia

               3. Subject has poor survival prognosis due to their arrhythmia

          7. Left ventricular ejection fraction (LVEF) &lt; 30%.

          8. Subject has undergone prior percutaneous coronary intervention (PCI) within the target
             vessel during the last 12 months. Prior PCI within the non-target vessel or any
             peripheral intervention is acceptable if performed anytime &gt;30 days before the index
             procedure, or between 24 hours and 30 days before the index procedure if successful
             and uncomplicated.

          9. Future staged PCI either in target or non-target vessels or subject requires future
             peripheral interventions &lt; 30 days after the index procedure.

         10. Subject has received any solid organ transplants or is on a waiting list for any solid
             organ transplants.

         11. At the time of screening, the subject has a malignancy that is not in remission.

         12. Subject is receiving immunosuppressant therapy or has known immunosuppressive or
             severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human
             immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are
             not included as immunosuppressant therapy.

         13. Subject has previously received or is scheduled to receive radiotherapy to a coronary
             artery (vascular brachytherapy), or the chest/mediastinum.

         14. Subject is receiving or will require chronic anticoagulation therapy (e.g., coumadin,
             dabigatran, apixaban, rivaroxaban or any other agent for any reason).

         15. Subject has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3.

         16. Subject has a documented or suspected hepatic disorder as defined as cirrhosis or
             Child-Pugh = Class B.

         17. Renal insufficiency. NOTE: Estimated glomerular filtration rate (GFR) can be based on
             Modification of Diet in Renal Disease (MDRD) equation or Cockcroft-Gault equation
             (CCG).

         18. High risk of bleeding for any reason; has a history of bleeding diathesis or
             coagulopathy; has had a significant gastro-intestinal or significant urinary bleed
             within the past six months.

         19. Cerebrovascular accident or transient ischemic neurological attack (TIA) within the
             past six months, or any prior intracranial bleed, or any permanent neurologic defect,
             or any known intracranial pathology (e.g., aneurysm, arteriovenous malformation,
             etc.).

         20. Extensive peripheral vascular disease that precludes safe 6 French sheath insertion.
             Note: femoral arterial disease does not exclude the patient if radial access may be
             used.

         21. Subject has life expectancy &lt; 5 years for any non-cardiac cause or cardiac cause.

         22. Subject is in the opinion of the Investigator or designee, unable to comply with the
             requirements of the study protocol or is unsuitable for the study for any reason. This
             includes completion of Patient Reported Outcome instruments.

         23. Subject is currently participating in another clinical trial that has not yet
             completed its primary endpoint.

         24. Vulnerable population.

        Angiographic Inclusion Criteria:

          1. One or two de novo target lesions:

               1. If there is one target lesion, a second non-target lesion may be treated but the
                  non-target lesion must be present in a different epicardial vessel, and must be
                  treated first with a successful, uncomplicated result prior to randomization of
                  the target lesion.

               2. If two target lesions are present, they must be present in different epicardial
                  vessels and both must satisfy the angiographic eligibility criteria.

               3. The definition of epicardial vessels means the LAD, LCX and RCA and their
                  branches. Thus, the patient must not have lesions requiring treatment in e.g.
                  both the LAD and a diagonal branch.

          2. Target lesion(s) must be located in a native coronary artery with a visually estimated
             or quantitatively assessed % diameter stenosis (DS) of = 50% and &lt; 100% with a
             thrombolysis in myocardial infarction (TIMI) flow of =1 and one of the following:
             stenosis = 70%, an abnormal functional test (e.g. fractional flow reserve, stress
             test), unstable angina or post-infarct angina.

               1. Lesion(s) must be located in a native coronary artery with RVD by visual
                  estimation of = 2.5 mm and = 3.75 mm.

               2. Lesion(s) must be located in a native coronary artery with length by visual
                  estimation of = 24 mm.

               3. For Lead-In subjects with 3.0x18 mm Absorb BVS: lesion(s) must be located in a
                  native coronary artery with RVD by visual estimation of = 2.75 mm and = 3.25 mm.
                  The lesion length by visual estimation is = 8 mm and = 14 mm.

        Angiographic 

        All exclusion criteria apply to the target lesion(s) or target vessel(s).

          1. Lesion which prevents successful balloon pre-dilatation, defined as full balloon
             expansion with the following outcomes:

               1. Residual %DS is a maximum of &lt; 40% (per visual estimation), = 20% is strongly
                  recommended.

               2. TIMI Grade-3 flow (per visual estimation).

               3. No angiographic complications (e.g. distal embolization, side branch closure).

               4. No dissections National Heart Lung and Blood Institute (NHLBI) grade D-F.

               5. No chest pain lasting &gt; 5 minutes.

               6. No ST depression or elevation lasting &gt; 5 minutes

          2. Lesion is located in left main.

          3. Aorto-ostial right coronary artery (RCA) lesion (within 3 mm of the ostium).

          4. Lesion located within 3 mm of the origin of the Left Anterior Descending Artery (LAD)
             or left circumflex artery (LCX).

          5. Lesion involving a bifurcation with a:

               1. side branch = 2 mm in diameter, or

               2. side branch with either an ostial or non-ostial lesion with diameter stenosis &gt;
                  50%, or

               3. side branch requiring dilatation.

          6. Anatomy proximal to or within the lesion that may impair delivery of the Absorb BVS or
             XIENCE stent:

               1. Extreme angulation (= 90) proximal to or within the target lesion.

               2. Excessive tortuosity (= two 45 angles) proximal to or within the target lesion.

               3. Moderate or heavy calcification proximal to or within the target lesion. If IVUS
                  used, subject must be excluded if calcium arc in the vessel prior to the lesion
                  or within the lesion is = 180.

          7. Vessel contains thrombus as indicated in the angiographic images or by IVUS or OCT.

          8. Lesion or vessel involves a myocardial bridge.

          9. Vessel has been previously treated with a stent at any time prior to the index
             procedure such that the Absorb BVS or XIENCE would need to cross the stent to reach
             the target lesion.

         10. Vessel has been previously treated and the target lesion is within 5 mm proximal or
             distal to a previously treated lesion.

         11. Target lesion located within an arterial or saphenous vein graft or distal to any
             arterial or saphenous vein graft.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>2250</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Liverpool Hospital - Liverpool BC</hospital>
    <hospital>The Prince Charles Hospital - Chermside</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Herston</hospital>
    <hospital>St. Vincent's Hospital Melbourne - Fitzroy</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>1871 - Liverpool BC</postcode>
    <postcode>4031 - Chermside</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>6000 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Montana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Vermont</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Abbott Vascular</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The ABSORB III RCT is a prospective randomized, single-blind, multi-center trial. It is the
      pivotal trial to support the US pre-market approval (PMA) of Absorb Bioresorbable Vascular
      Scaffold (BVS).

      The ABSORB III includes additional two trials i.e. ABSORB III PK (pharmacokinetics) sub-study
      and ABSORB IV RCT trial which are maintained under one protocol because both trial designs
      are related, ABSORB IV is the continuation of ABSORB III and the data from ABSORB III and
      ABSORB IV will be pooled to support the ABSORB IV primary endpoint. Both the trials will
      evaluate the safety and effectiveness of Absorb BVS.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01751906</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Stephen G Ellis, MD</name>
      <address>Cleveland Clinic, Cleveland OH</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Diane Williams</name>
      <address />
      <phone>408 845-3000</phone>
      <fax />
      <email>AbsorbRCT@abbott.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>